ADC Therapeutics Gets European Commission Approval Of Zynlonta For The Treatment Of Relapsed Or Refractory Diffuse Large B-cell Lymphoma’
https://ec.europa.eu/transparency/documents-register/detail?ref=C(2022)9955&lang=en
Satsuma Pharmaceuticals Says Analysis Of Results From Recently-Completed Summit Phase 3 Efficacy Trial Of Sts101 For The Acute Treatment Of Migraine Shows Differentiating Robust, Sustained Antimigraine Effects On Clinically Important Secondary Endpoint…
Satsuma Pharmaceuticals Provides STS101 Development Program and Corporate Update
Further analysis of results from recently-completed SUMMIT Phase 3 efficacy trial of STS101 for the acute treatment of migraine shows
Athenex Announces Quantum Leap Healthcare Collaborative Reports Trial Result Of I-SPY2 Trial For Oral Paclitaxel In Combination With PD-1 And Carboplatin In Neoadjuvant Breast Cancer
Athenex, Inc., (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions announced that
MAIA Biotechnology Holds Successful Pre-IND Meeting With FDA For Planned U.S. Expansion Of THIO-101 Phase 2 Trial For Non-Small Cell Lung Cancer
MAIA Biotechnology, Inc. (NYSE American: MAIA) ("MAIA," "the Company") today announced that it completed a pre-Investigational New Drug (pre-IND) meeting with the U.S. Food and Drug
Iveric Bio Announces Completion Of Rolling NDA Submission To FDA For Avacincaptad Pegol For The Treatment Of Geographic Atrophy
IVERIC bio, Inc. (NASDAQ:ISEE) today announced that it has submitted to the U.S. Food and Drug Administration (FDA) the third and final part of its New Drug Application (NDA) for rolling review of avacincaptad pegol
ANI Pharmaceuticals Announces FDA Approval And Launch Of Levocarnitine Tablets USP
ANI Pharmaceuticals, Inc. (ANI or the Company) (NASDAQ:ANIP) today announced that it received U.S. Food and Drug Administration (FDA) approval for the Abbreviated New Drug Application (ANDA) for Levocarnitine Tablets
Why Entrada Therapeutics Stock Is Diving After Hours
Entrada Therapeutics Inc (NASDAQ: TRDA) shares are trading lower in Monday's after-hours session after the company said it received a clinical hold notice from the
Entrada Therapeutics Announces Clinical Hold On IND Application For ENTR-601-44 In Duchenne Muscular Dystrophy
Entrada Therapeutics, Inc. (NASDAQ:TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal Escape Vehicle (EEV™)-therapeutics as a new class of
Nuvation Bio Doses First Patient In Phase 1b Combination Study Of NUV-868
Phase 1b study designed to determine the safety and dose of NUV-868 in combination with olaparib or enzalutamide for the treatment of advanced solid tumors
Nuvation Bio Inc. (NYSE:NUVB), a biopharmaceutical company
Verona Pharma To Announce Top-line Data From Phase 3 ENHANCE-1 Trial Of Nebulized Ensifentrine For COPD On Tuesday, December 20, 2022
Verona Pharma plc (NASDAQ:VRNA) ("Verona Pharma" or the "Company"), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces it will report top-line Phase 3 data from its